News

The recommendation for granting Type II variation approval supports the use of cilta-cel for adult patients with RRMM who have received a minimum of one therapy earlier, including

Artiva had previously secured FDA clearance for an investigational new drug application for AlloNK plus rituximab for LN. This marked the first IND clearance for an allogeneic, off-the-shelf

Concurrently, the European Medicines Agency (EMA) granted accelerated assessment for the marketing authorization application (MAA) of the same drug. On receipt of approval, vorasidenib would become the sixth

The financing round was spearheaded by Broadview Ventures, with additional support from current investor SCVC and new participant MEIF Proof of Concept & Early Stage Fund. Mercia Ventures

This decision grants Everest the full ownership of intellectual property rights and worldwide rights for these products. The latest development is aimed at enhancing Everest’s flexibility in aligning

A humanised IgG2 monoclonal antibody, sibeprenlimab acts on the B-cell growth factor dubbed APRIL, a critical player in IgAN’s development and progression. By neutralising APRIL, the drug aims

This review could potentially lead to the approval of the first combination treatment offering an alternative to platinum-containing chemotherapy as the first-line treatment for locally advanced or metastatic

ATA3219 utilises allogeneic T cells to act on the CD19 antigen found on B cells, which are implicated in B-cell mediated autoimmune diseases such as systemic lupus erythematosus

Ally Bridge Group led the funding round, which saw contributions from healthcare focused and mutual fund institutional investors. New investors comprised Nextech Invest, funds and accounts advised by